Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Imidazopyrazines Kill the Malaria Parasite at Every Stage of Its Life Cycle

By BiotechDaily International staff writers
Posted on 09 Dec 2013
Image: Malaria parasites (labeled with fluorescent protein) in the late stages of development, superimposed on a field of red blood cells. The many nuclei of the parasites\' daughter cells are labeled in blue, and the plasma membranes surrounding the daughter cells are labeled in green. Imidazopyrazine treatment disrupts formation of the membranes around the daughter cells (Photo courtesy of Dr. Marcus C.S. Lee, Columbia University Medical Center).
Image: Malaria parasites (labeled with fluorescent protein) in the late stages of development, superimposed on a field of red blood cells. The many nuclei of the parasites\' daughter cells are labeled in blue, and the plasma membranes surrounding the daughter cells are labeled in green. Imidazopyrazine treatment disrupts formation of the membranes around the daughter cells (Photo courtesy of Dr. Marcus C.S. Lee, Columbia University Medical Center).
An enzyme that is vital to all life stages of several species of malaria parasites has been cited as a tempting target for drug developers.

Achieving the goal of malaria elimination will depend on targeting pathways essential across all life stages of the parasite, Plasmodium. Towards this end, investigators at Columbia University Medical Center (New York, NY, USA) collaborated with an international team of researchers to screen more than a million drug compounds against the most lethal malaria parasite, Plasmodium falciparum, in order to identify compounds capable of killing the parasite at each stage of its life cycle.

They reported in the November 27, 2013, online edition of the journal Nature that the class of compounds called imidazopyrazines was capable of inhibiting the intracellular development of P. falciparum and several other species including P. vivax and P. cynomolgi at every stage of infection in the vertebrate host.

Imidazopyrazines demonstrated potent preventive, therapeutic, and transmission-blocking activity in rodent malaria models and were active against blood-stage field isolates of the major human pathogens P. falciparum and P. vivax. In addition, they inhibited liver-stage hypnozoites in the simian parasite P. cynomolgi.

The target of imidazopyrazine inhibition was found to be the enzyme phosphatidylinositol 4-kinase (PI(4)K). Imidazopyrazines altered the intracellular distribution of phosphatidylinositol-4-phosphate in the parasite's Golgi organelle by occupying PI(4)K's ATP-binding pocket.

“We think that disrupting the function of PI(4)K at the Golgi stops the parasite from making new membranes around its daughter cells, thereby preventing the organism from reproducing,” said senior author Dr. Marcus C. S. Lee, associate research scientist in microbiology and immunology at Columbia University Medical Center.

“Perhaps the most exciting aspect of our findings is that this enzyme is required at all stages of the parasites’ life cycle in humans,” said Dr. Lee. “This is important because most antimalarials are effective at killing the parasites only as they circulate in the bloodstream. However, the parasites can hide in the liver for years before reemerging and triggering a relapse of the disease. By identifying this enzyme, we may be able to develop a new way to kill the parasites in their dormant stage.”

Related Links:

Columbia University Medical Center



Channels

Genomics/Proteomics

view channel
Image: The bone marrow of mice with normal ether lipid production (top) contains more white blood cells than are found in the bone marrow of mice with ether lipid deficiency (bottom) (Photo courtesy of Washington University School of Medicine).

Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition. Neutrophils are the most abundant... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.